201 related articles for article (PubMed ID: 26872993)
1. ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy.
Nagy L; Pollesello P; Haikala H; Végh Á; Sorsa T; Levijoki J; Szilágyi S; Édes I; Tóth A; Papp Z; Papp JG
Eur J Pharmacol; 2016 Mar; 775():120-9. PubMed ID: 26872993
[TBL] [Abstract][Full Text] [Related]
2. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone.
Szilágyi S; Pollesello P; Levijoki J; Haikala H; Bak I; Tósaki A; Borbély A; Edes I; Papp Z
J Cardiovasc Pharmacol; 2005 Sep; 46(3):369-76. PubMed ID: 16116344
[TBL] [Abstract][Full Text] [Related]
3. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition.
Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895
[TBL] [Abstract][Full Text] [Related]
4. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig.
Szilágyi S; Pollesello P; Levijoki J; Kaheinen P; Haikala H; Edes I; Papp Z
Eur J Pharmacol; 2004 Feb; 486(1):67-74. PubMed ID: 14751410
[TBL] [Abstract][Full Text] [Related]
5. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan.
Haikala H; Kaheinen P; Levijoki J; Lindén IB
Cardiovasc Res; 1997 Jun; 34(3):536-46. PubMed ID: 9231037
[TBL] [Abstract][Full Text] [Related]
6. The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts.
Kristof E; Szigeti G; Papp Z; Bodi A; Ball NA; Walsh RA; Edes I
Basic Res Cardiol; 1999 Aug; 94(4):223-30. PubMed ID: 10505421
[TBL] [Abstract][Full Text] [Related]
7. Calcium sensitization in perfused beating guinea pig heart by a positive inotropic agent MCI-154.
Abe Y; Ishisu R; Onishi K; Sekioka K; Narimatsu A; Nakano T
J Pharmacol Exp Ther; 1996 Feb; 276(2):433-9. PubMed ID: 8632307
[TBL] [Abstract][Full Text] [Related]
8. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 1st communication: phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea-pig heart.
Hino M; Sugawara H; Yoshimura A; Ogura A; Yoshioka K; Sakato M; Endoh M
Arzneimittelforschung; 1999 May; 49(5):398-406. PubMed ID: 10367101
[TBL] [Abstract][Full Text] [Related]
9. Comparison of enoximone, amrinone, or levosimendan enriched St. Thomas' hospital cardioplegic solutions used for myocardial preservation in isolated guinea pig hearts.
Köksal C; Süzer O; Bozkurt AK; Köseoğlu S
Acta Medica (Hradec Kralove); 2002; 45(3):93-7. PubMed ID: 12515045
[TBL] [Abstract][Full Text] [Related]
10. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.
Edes I; Kiss E; Kitada Y; Powers FM; Papp JG; Kranias EG; Solaro RJ
Circ Res; 1995 Jul; 77(1):107-13. PubMed ID: 7788868
[TBL] [Abstract][Full Text] [Related]
11. The effects of levosimendan on myocardial function in ropivacaine toxicity in isolated guinea pig heart preparations.
Stehr SN; Christ T; Rasche B; Rasche S; Wettwer E; Deussen A; Ravens U; Koch T; Hübler M
Anesth Analg; 2007 Sep; 105(3):641-7. PubMed ID: 17717217
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Orstavik O; Ata SH; Riise J; Dahl CP; Andersen GØ; Levy FO; Skomedal T; Osnes JB; Qvigstad E
Br J Pharmacol; 2014 Dec; 171(23):5169-81. PubMed ID: 24547784
[TBL] [Abstract][Full Text] [Related]
13. The cardiotonic effects of levosimendan in guinea pig hearts are modulated by beta-adrenergic stimulation.
Bódi A; Szilágyi S; Edes I; Papp Z
Gen Physiol Biophys; 2003 Sep; 22(3):313-27. PubMed ID: 14986883
[TBL] [Abstract][Full Text] [Related]
14. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?
Zimmermann N; Boknik P; Gams E; Herzig JW; Neumann J; Scholz H
Eur J Cardiothorac Surg; 1998 Jul; 14(1):70-5. PubMed ID: 9726618
[TBL] [Abstract][Full Text] [Related]
15. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.
Harkin CP; Pagel PS; Tessmer JP; Warltier DC
J Cardiovasc Pharmacol; 1995 Aug; 26(2):179-88. PubMed ID: 7475041
[TBL] [Abstract][Full Text] [Related]
16. In vivo evidence of positive inotropism of EMD 57033 through calcium sensitization.
Haeusler G; Jonas R; Minck KO; Schliep HJ; Schelling P; Weygandt H; Lues I
J Cardiovasc Pharmacol; 1997 May; 29(5):647-55. PubMed ID: 9213208
[TBL] [Abstract][Full Text] [Related]
17. Calcium sensitisation impairs diastolic relaxation in post-ischaemic myocardium: implications for the use of Ca(2+) sensitising inotropes after cardiac surgery.
Choi YH; Cowan DB; Wahlers TC; Hetzer R; Del Nido PJ; Stamm C
Eur J Cardiothorac Surg; 2010 Feb; 37(2):376-83. PubMed ID: 19616444
[TBL] [Abstract][Full Text] [Related]
18. The Effect of a Novel Highly Selective Inhibitor of the Sodium/Calcium Exchanger (NCX) on Cardiac Arrhythmias in In Vitro and In Vivo Experiments.
Kohajda Z; Farkas-Morvay N; Jost N; Nagy N; Geramipour A; Horváth A; Varga RS; Hornyik T; Corici C; Acsai K; Horváth B; Prorok J; Ördög B; Déri S; Tóth D; Levijoki J; Pollesello P; Koskelainen T; Otsomaa L; Tóth A; Baczkó I; Leprán I; Nánási PP; Papp JG; Varró A; Virág L
PLoS One; 2016; 11(11):e0166041. PubMed ID: 27832106
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects of ATI22-107 [2-(2-{2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino}-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester)], a novel dual pharmacophore, on myocyte calcium cycling and contractility.
Jung AS; Quaile MP; Mills GD; Bednarik DP; Houser SR; Margulies KB
J Pharmacol Exp Ther; 2005 Feb; 312(2):517-24. PubMed ID: 15550574
[TBL] [Abstract][Full Text] [Related]
20. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 3rd communication: stereoselectivity of the enantiomers in cardiovascular effects.
Sugawara H; Hino M; Yoshimura A; Yoshioka K; Sakato M; Endoh M
Arzneimittelforschung; 1999 May; 49(5):412-9. PubMed ID: 10367103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
